Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Phase Forward and Merck project wins the Society for Clinical Data Management Data Driven Innovation Award

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced that a joint project with customer Merck & Co. has won the 2009 Society for Clinical Data Management (SCDM) Data Driven Innovation Award competition. This annual honor recognizes the year’s best advancement in clinical data management technology or service.

15 Oct 2009

Serametrix and the Ludwig Institute for Cancer Research form a partnership

Serametrix Corporation, a personalized medicine company, today announced their partnership with the Ludwig Institute for Cancer Research Ltd. (LICR). The agreement will combine LICR’s historic discoveries in tumor immunology with the technologies and commercial capabilities of Serametrix. This new alliance will enable rapid development and commercialization of tests that predict and monitor drug response in cancer patients. The serum-based tests, which determine immune reaction to tumor antigens, are of value to clinicians and drug developers alike.

15 Oct 2009

SwitchGear Genomics introduces high-throughput research tools for profiling biological pathway regulation

SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, today announced the availability of the first cost-effective, high-throughput research tools for screening transcriptional activation and repression in a number of key biological pathways.

14 Oct 2009

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

14 Oct 2009

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

Integrated Diagnostics launched officially today with more than $30 million in funding. A pre-eminent team of scientists and investors are behind the company, which was founded by renowned biotechnology innovator Dr. Leroy Hood. Integrated Diagnostics will focus on developing personalized and preventive diagnostics based on breakthroughs using genomic and proteomic technologies to identify organ-specific proteins.

14 Oct 2009

Researchers develop magneto-nano sensor chip to detect cancer

Searching for biomarkers that can warn of diseases such as cancer while they are still in their earliest stage is likely to become far easier thanks to an innovative biosensor chip developed by Stanford University researchers.

14 Oct 2009

Geniom RT Analyzer provides accurate diagnosis of multiple sclerosis and lung cancer disorders

Data published in BMC Cancer and PLoS ONE show that microRNA (miRNA) biomarkers provide reliable and highly differentiated diagnosis from blood samples for lung cancer and multiple sclerosis.

14 Oct 2009

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Champions Biotechnology, Inc., a drug development company with a preclinical platform able to predict clinical effectiveness, accelerate development and enhance the value of oncology drugs, today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410.

14 Oct 2009

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Individuals with Parkinson's disease who have higher levels of a metabolite called urate in their blood and in cerebrospinal fluid (CSF) have a slower rate of disease progression, according to a study funded by the National Institutes of Health.

14 Oct 2009

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month.

13 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Orion Genomics today announced that it has entered into a multi-year collaboration and license agreement with the molecular diagnostics unit of Novartis Pharma AG. Under the collaboration, the parties seek to discover novel epigenetic biomarkers, and both parties have rights to independently develop and commercialize diagnostic products in their respective fields.

12 Oct 2009

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Raptor Pharmaceutical Corp., announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.

12 Oct 2009

Canary Foundation to implement biosensor technologies for early cancer detection

Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.

12 Oct 2009

Health Discovery retains Dilenschneider Group to manage its investor and media relations work

Health Discovery Corporation, is pleased to announce that it has retained The Dilenschneider Group, headquartered in New York City, to manage the Company’s investor and media relations work. With offices in New York, Washington, DC and Chicago, the Dilenschneider Group provides its clients with some of the finest and most seasoned communications professionals in the world.

9 Oct 2009

NIH grants over $3.8 million to Asuragen

Asuragen, Inc. announced today that it has received over $3.8 million in new grant funding for 2009 from the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and American Recovery and Reinvestment Act (ARRA) funded initiatives of the National Institutes of Health (NIH) to further its development of molecular diagnostics for oncology and genetic disease.

8 Oct 2009

NCI awards BioMarker Strategies a SBIR contract to develop its SnapPath live-tumor-cell testing system

BioMarker Strategies, LLC announced today that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) contract from the National Cancer Institute to develop the SnapPath™ live-tumor-cell testing system. BioMarker Strategies is developing the SnapPath™ system to enable oncologists to determine the most effective drug treatment for their cancer patients.

7 Oct 2009

Clinical Genomics extends collaboration with CSIRO

Sydney-based Clinical Genomics Pty Ltd and CSIRO have entered into a new phase in their collaboration to develop improved diagnostics for cancers of the colon and rectum (bowel cancer).

7 Oct 2009

ABT Molecular Imaging secures $9 million through its Series A financing

ABT Molecular Imaging, a medical imaging company developing a production platform to generate unit doses of molecular imaging drugs, announced today it has secured a $9 million round of financing.

7 Oct 2009

Triage NGAL Test allows early identification of AKI in ICU patients

According to a new study now available online, and to be published in an upcoming issue of the Journal of Critical Care, bedside testing for a blood biomarker called neutrophil gelatinase-associated lipocalin (NGAL) in patients being admitted to the intensive care unit can help to identify patients at risk for acute kidney injury (AKI).

6 Oct 2009

Biomarker News and Research

Further Reading

Phase Forward and Merck project wins the Society for Clinical Data Management Data Driven Innovation Award

Serametrix and the Ludwig Institute for Cancer Research form a partnership

SwitchGear Genomics introduces high-throughput research tools for profiling biological pathway regulation

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

Researchers develop magneto-nano sensor chip to detect cancer

Geniom RT Analyzer provides accurate diagnosis of multiple sclerosis and lung cancer disorders

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Canary Foundation to implement biosensor technologies for early cancer detection

Health Discovery retains Dilenschneider Group to manage its investor and media relations work

NIH grants over $3.8 million to Asuragen

NCI awards BioMarker Strategies a SBIR contract to develop its SnapPath live-tumor-cell testing system

Clinical Genomics extends collaboration with CSIRO

ABT Molecular Imaging secures $9 million through its Series A financing

Triage NGAL Test allows early identification of AKI in ICU patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News